Cargando…

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study

Background: Central obesity is associated with increased risk of cardiometabolic disease. Weight loss reduces lean muscle mass, potentially impacting resting energy expenditure and/or physical functioning. This analysis of the STEP 1 trial evaluated the impact of subcutaneous (s.c.) semaglutide, a g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilding, John P H, Batterham, Rachel L, Calanna, Salvatore, Van Gaal, Luc F, McGowan, Barbara M, Rosenstock, Julio, Tran, Marie T D, Wharton, Sean, Yokote, Koutaro, Zeuthen, Niels, Kushner, Robert F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089287/ http://dx.doi.org/10.1210/jendso/bvab048.030

Ejemplares similares

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS
por: Jensterle, Mojca, et al.
Publicado: (2022)

Profile of Intestinal Microbiota and Anxiety Level in Overweight Children and Adolescents
por: Bandeira Farias, Maria Paula Costa, et al.
Publicado: (2021)

Cancer Risk of Patients With Overweight and Obesity: A Predictive Model
por: Turchin, Alexander, et al.
Publicado: (2021)

SAT-103 Assessing Factors Influencing Eating in Overweight and Obese Individuals
por: DiBenedetti, Dana, et al.
Publicado: (2019)

FRI007 Kisspeptin Does Not Affect Food Intake In Women With Overweight Or Obesity
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023)

Neurobiology of Avoidant/Restrictive Food Intake Disorder in Youth With Overweight/Obesity Versus Healthy Weight
por: Liya, Kerem, et al.
Publicado: (2021)

SAT659 Prevalence Of Multimorbidity Across Age Groups Among Us Adults With Overweight Or Obesity
por: Ezendu, Kyrian, et al.
Publicado: (2023)

SAT657 Work Loss Among Privately Insured Employees With Overweight And Obesity In The United States
por: Shinde, Shraddha, et al.
Publicado: (2023)

SAT-096 Later Timing of Energy Intake Associates with Higher Fat Mass in Adults with Overweight and Obesity
por: Zaman, Adnin, et al.
Publicado: (2019)

ODP009 Obesity-related Conditions in Adults with Overweight and Obesity in the United States: A Cluster Analysis
por: Chiu, Kevin, et al.
Publicado: (2022)

FRI030 The Clinical Significance Of The Oxidative Status Evaluation Among Insulin Resistant Overweight And Obese Patients
por: Popławska-Kita, Anna, et al.
Publicado: (2023)

SAT664 Obesity And Overweight Diagnosis, Physician Prescription And Patient Filling Of Anti-Obesity Medications In US
por: Ezendu, Kyrian, et al.
Publicado: (2023)

SAT-094 Overweight and Obesity Associated with Immune-Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapy
por: Leiter, Amanda, et al.
Publicado: (2019)

FRI050 A Cross-sectional Study Of Parental Outdoor Play Preferences And Association With Child Overweight And Obesity
por: Gavryutina, Irina, et al.
Publicado: (2023)

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
por: Srinath, Reshmi, et al.
Publicado: (2023)

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity
por: Ji, Linong, et al.
Publicado: (2022)

FRI029 Chronic Free Fatty Acid Elevation Is Associated With An Overcompensatory Increase In Hepatic Mitochondrial Function In Patients With Overweight Or Obesity
por: Bril, Fernando, et al.
Publicado: (2023)

MON-112 Gelesis100 Reduces Insulin Resistance in Patients Who Are Overweight or Have Obesity with High Insulin Resistance: Results of the GLOW Study
por: Greenway, Frank, et al.
Publicado: (2019)

SAT679 Telehealth And Metabolic Health: Unraveling The Effects Of A 12-week Low-starch Diet On Homa2B IR In Overweight Women
por: Erta, Gita, et al.
Publicado: (2023)

OR20-2 Oxytocin Significantly Attenuates the Functional Connectivity between Food Motivation Brain Areas in Overweight and Obese Men Exposed to High Caloric Food Images
por: Kerem, Liya, et al.
Publicado: (2019)

RF24 | PSUN110 A Cross-Sectional Study Evaluating the Impact of Combined Hormonal Contraceptives on Components of Energy Balance in Pre-Menopausal Women with Overweight or Obesity
por: Zaman, Adnin, et al.
Publicado: (2022)

FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis
por: Silva, Caroliny Hellen, et al.
Publicado: (2023)

ODP004 Glucose Profiles and Insulin Sensitivity in Adults with Overweight/Obesity Participating in a Weight Loss Intervention based on Early Time-Restricted Eating plus Daily Caloric Restriction vs Daily Caloric Restriction Alone
por: Jeffers, Rebecca, et al.
Publicado: (2022)

RF24 | PSUN94 Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Woloschak, Michael, et al.
Publicado: (2022)

OR10-2 Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
por: Abuzzahab, Jennifer, et al.
Publicado: (2022)

FRI026 PPARγ Antagonists Induce Aromatase Transcription In Human Adipose Tissue Cells
por: Ardenkjær-Skinnerup, Jacob, et al.
Publicado: (2023)

The Effectiveness of Adding Pharmacotherapy to Dietary Counseling for Veterans in a Veterans Health Administration Move! Weight Management Program
por: Alvarez, Diego Alcaraz, et al.
Publicado: (2021)

Anti-Obesity Medication Prescriptions by Race/Ethnicity and Use of an Interpreter in a Pediatric Weight Management Clinic
por: Bomberg, Eric M, et al.
Publicado: (2021)

FRI005 Appetite Response To Short-term Energy Restriction In Young Healthy Women
por: Choi, Gloria E, et al.
Publicado: (2023)

FRI046 Clinical Phenotyping Of Adults With Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2023)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Hair Cortisol, Obesity and the Immune System: Results From a 3 Year Longitudinal Study
por: van der Valk, Eline S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_77qpre0clvectgdvc0g9191ud8